
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
PAREXEL International Corporation, global biopharma services provider, and Osaka International Cancer Institute announced that they have formed a partnership to advance clinical development in Japan. Together, they aim to drive efficiencies in support of patient recruitment for clinical trials in oncology and hematology, and to develop new cancer treatments for patients.
Read the full release






